TY  - JOUR
AU  - Baertsch, Marc-Andrea
AU  - Schlenzka, Jana
AU  - Hielscher, Thomas
AU  - Raab, Marc S
AU  - Sauer, Sandra
AU  - Merz, Maximilian
AU  - Mai, Elias K
AU  - Müller-Tidow, Carsten
AU  - Luntz, Steffen
AU  - Jauch, Anna
AU  - Brossart, Peter
AU  - Goerner, Martin
AU  - Klein, Stefan
AU  - Glass, Bertram
AU  - Reimer, Peter
AU  - Graeven, Ullrich
AU  - Fenk, Roland
AU  - Haenel, Mathias
AU  - von Metzler, Ivana
AU  - Lindemann, Hans-Walter
AU  - Scheid, Christof
AU  - Blau, Igor-Wolfgang W
AU  - Salwender, Hans J
AU  - Noppeney, Richard
AU  - Besemer, Britta
AU  - Weisel, Katja C
AU  - Goldschmidt, Hartmut
TI  - Salvage Autologous Transplant in Relapsed Multiple Myeloma: Long-Term Follow-Up of the Phase 3 GMMG ReLApsE Trial.
JO  - Blood
VL  - 145
IS  - 16
SN  - 0006-4971
CY  - Washington, DC
PB  - American Society of Hematology
M1  - DKFZ-2025-00139
SP  - 1780-1787
PY  - 2025
N1  - 2025 Apr 17;145(16):1780-1787
AB  - The multicenter, phase III GMMG ReLApsE trial (EudraCT-No:2009-013856-61) randomized relapsed and/or refractory multiple myeloma (RRMM) patients equally to lenalidomide/dexamethasone (LEN/DEX, 25mg days 1-21/40mg weekly, 4-week cycles) re-induction, salvage high dose chemotherapy (sHDCT, melphalan 200mg/m2), autologous stem cell transplantation (ASCT) and LEN maintenance (10mg/day; transplant arm, n=139) versus continuous LEN/DEX (control arm, n=138). Ninety-four percent of patients had received frontline HDCT/ASCT. We report an updated analysis of survival endpoints with a median follow-up of 99 months. Median progression-free survival (PFS) was 20.5 and 19.3 months in the transplant and control arm, respectively (HR 0.98; 95
LB  - PUB:(DE-HGF)16
C6  - pmid:39808798
DO  - DOI:10.1182/blood.2024027342
UR  - https://inrepo02.dkfz.de/record/297962
ER  -